Navigation Links
Tocagen Expands Clinical Development Team;
Date:8/26/2014

SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Tocagen Inc. today announced Wayne Saville, M.D., has been named vice president, clinical development, and Mary Rose Keller has been named vice president, clinical operations.

"As we advance Toca 511 & Toca FC into late-stage registration studies, we are expanding our clinical team with individuals who have deep experience in drug development, regulatory approval, launch and commercialization activities," said Jamey Skillings, M.D., Chief Medical Officer of Tocagen. "Wayne and Mary Rose bring decades of valuable expertise in clinical development and medical affairs at a pivotal time for Tocagen."

Dr. Saville has more than a decade of experience in clinical development and medical affairs for cancer products. Prior to joining Tocagen, he headed medical affairs at Genoptix, an oncology diagnostics laboratory acquired by Novartis. Previous to that position he was a director of clinical research at Amgen, where he led late-stage development of a cancer drug as well as medical affairs for Prolia. Prior to this role, Dr. Saville was the director of oncology clinical research at Biogen Idec, leading clinical and medical affairs programs for Zevalin® and Rituxan®. Previous to this position, he was an associate professor at the University of California, San Diego, and trained in internal medicine at the University of Minnesota Medical Center. He was a medical oncology fellow at the National Cancer Institute and obtained his medical degree and bachelor's degree in medicine at Northwestern University. 

Ms. Keller has more than two decades of experience in drug development and clinical operations, and has worked with numerous research-focused organizations while at University of California, San Francisco's Cancer Research Institute, including the Brain Tumor Research Group, Children's Cancer Study Group and Radiation Therapy Oncology Group. Previously she was the vice president of clinical development and operations at a number of pharmaceutical companies including Prometheus Laboratories and Shire. Prior, she was the senior director of clinical operations at Agouron, leading activities for Viracept®. She subsequently led Agouron's oncology and ophthalmology programs through mergers with Warner-Lambert and Pfizer, ultimately becoming Pfizer's worldwide head development operations, global team leads and clinical trial recruitment services. Ms. Keller also previously worked at New Drug Services, where she participated in eight New Drug Applications. Ms. Keller obtained her bachelor's degree at the University of California, Davis.

About Tocagen Inc.
Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene therapy products for the selective treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist. Toca 511 & Toca FC, the company's lead investigational combination product, is being evaluated in three clinical trials in patients with recurrent high grade glioma, including glioblastoma (GBM). Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information about Tocagen or Toca 511 please visit www.tocagen.com or www.clinicaltrials.gov using the identifier NCT01470794NCT01156584 or NCT01985256


'/>"/>
SOURCE Tocagen Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
2. Six Presentations on Tocagens Toca 511 to be Given at the Society of Neuro-Oncology Annual Meeting
3. Data Presented at Society for Neuro-Oncology Annual Meeting Demonstrate Tocagens Toca 511 Gene Therapy with Toca FC was Well Tolerated and Showed Antitumor Activity in Patients with High Grade Glioma
4. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
5. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
6. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
7. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. PRA Expands Operations in Europe
10. USANA Health Sciences Expands Award-Winning Research and Development Team
11. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
(Date:2/5/2016)... 2016 --> ... that the global active pharmaceuticals ingredients (APIs) market stood ... reach US$185.9 bn by 2020. It is expected to ... 2020. The title of the report is "Active Pharmaceutical ... and by Therapeutic Area) - Global Industry Analysis, Size, ...
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Regular gym ... find themselves having to wait longer to access the treadmills. It’s a predictable trend. ... resolutions to lose weight and get in shape by joining gyms, starting new walking ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers ... the start of Project HoldSpace. Through the partnership, the two organizations seek to ... youth between the ages of 13 and 18. Currently focused on Ohio schools, ...
Breaking Medicine News(10 mins):